Dr Benagiano's opening debate (Benagiano, 1998) raises several important issues. His suggestion-that regulatory authorities should only act after publication of the relevant data,-would, if accepted, seriously endanger public safety. For it is, of course, regulatory authorities and not the editors of scientific journals who are ultimately responsible for protecting the public health. Failure of a regulatory authority to act in the face of a hazard, merely because the relevant data had not been published, would have unfortunate public health consequences and could be tantamount to negligence. Dr Benagiano appears to be unaware that modern drug regulation incorporates a process of peer review which goes far beyond that of any scientific journal. The UK's Medicines Control Agency (MCA) and Committee on Safety of Medicines (CSM) have, collectively, scientific expertise that would be the envy of any journal editor. Moreover, writing as someone who has been involved in the peer review process on many hundreds of occasions, the time and effort expended by the CSM and MCA in reviewing important new evidence is an order of magnitude greater than that involved in peer review for a journal.
It is, obviously, preferable for the regulatory position to be coordinated with publication of the data so that the evidence is available to all. This is, indeed, our policy to do so wherever possible, and I am grateful to journal editors for facilitating this. Last year, for example, we were able to ensure that the publication the meta-analysis of Hormone Replacement therapy and breast cancer (Collaborative Group on Hormonal Factors in Breast Cancer, 1997), in the Lancet, coincided with advice to prescribers and patients using the Epinet messaging system and the Internet (http://www.open.gov.uk/mca/epinet7.htm).
Dr Benagiano alleges that the advice given by the CSM in October 1995 was 'action amounting to a ban'. This is completely misleading: both British health professionals, and the public, know that if we believe that a particular pharmaceutical product should no longer be used we say so. In the case of oral contraceptives containing desogestrel or gestodene the clear advice in my letter (CSM, 1995) to prescribers was to avoid their use in patients at high risk of venous © European Society for Human Reproduction and Embryology 1781 thromboembolism (VTE); and to target them towards women who had good reasons for using them, and were aware of the increased risk. I therefore totally reject Dr Benagiano's presumption that we were unable to address three vital issues before formulating our advice. The issue of causality, and the clinical and public health implications, were subject to detailed consideration and debate on the basis of information from three studies (Rawlins, 1995) . Our advice was based on the expectation that around 100-150 cases of VTE, and 1-2 deaths per annum, would be prevented; and that there was no good evidence of benefit to offset these additional risks. The information was not materially changed when the data were eventually published.
